- Home
- AIIOW vs WGSWW Comparison
AIIOW vs WGSWW Comparison
Compare AIIOW & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIIOW | WGSWW |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United Arab Emirates | United States |
| Employees | 68 | 1000 |
| Industry | Auto Manufacturing | Retail: Computer Software & Peripheral Equipment |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AIIOW | WGSWW |
|---|---|---|
| Price | $0.06 | $0.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 36.6K |
| Earning Date | N/A | 02-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $305,450,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.79 |
| 52 Week Low | N/A | $0.17 |
| 52 Week High | N/A | $0.21 |
Technical Indicators
Market Signals| Indicator | AIIOW | WGSWW |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 38.02 |
| Support Level | N/A | $0.02 |
| Resistance Level | N/A | $0.04 |
| Average True Range (ATR) | 0.00 | 0.01 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 28.36 |
Price Performance
Historical ComparisonAbout AIIOW Robo.ai Inc. Warrant
Robo.ai Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world. Geographically, the company operates in The United States, The United Arab Emirates, Mainland China.
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.